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Abstract
Background: Although the high mobility group A1 (HMGA1) gene is widely overexpressed in diverse cancers and
portends a poor prognosis in some tumors, the molecular mechanisms that mediate its role in transformation have
remained elusive. HMGA1 functions as a potent oncogene in cultured cells and induces aggressive lymphoid
tumors in transgenic mice. Because HMGA1 chromatin remodeling proteins regulate transcription, HMGA1 is
thought to drive malignant transformation by modulating expression of specific genes. Genome-wide studies to
define HMGA1 transcriptional networks during tumorigenesis, however, are lacking. To define the HMGA1
transcriptome, we analyzed gene expression profiles in lymphoid cells from HMGA1a transgenic mice at different
stages in tumorigenesis.
Results: RNA from lymphoid samples at 2 months (before tumors develop) and 12 months (after tumors are
well-established) was screened for differential expression of > 20,000 unique genes by microarray analysis
(Affymetrix) using a parametric and nonparametric approach. Differential expression was confirmed by
quantitative RT-PCR in a subset of genes. Differentially expressed genes were analyzed for cellular pathways
and functions using Ingenuity Pathway Analysis. Early in tumorigenesis, HMGA1 induced inflammatory
pathways with NFkappaB identified as a major node. In established tumors, HMGA1 induced pathways
involved in cell cycle progression, cell-mediated immune response, and cancer. At both stages in
tumorigenesis, HMGA1 induced pathways involved in cellular development, hematopoiesis, and hematologic
development. Gene set enrichment analysis showed that stem cell and immature T cell genes are enriched in
the established tumors. To determine if these results are relevant to human tumors, we knocked-down HMGA1
in human T-cell leukemia cells and identified a subset of genes dysregulated in both the transgenic and
human lymphoid tumors.
Conclusions: We found that HMGA1 induces inflammatory pathways early in lymphoid tumorigenesis and
pathways involved in stem cells, cell cycle progression, and cancer in established tumors. HMGA1 also dyregulates
genes and pathways involved in stem cells, cellular development and hematopoiesis at both early and late stages
of tumorigenesis. These results provide insight into HMGA1 function during tumor development and point to
cellular pathways that could serve as therapeutic targets in lymphoid and other human cancers with aberrant
HMGA1 expression.
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The high mobility group A1 gene (HMGA1)i sh i g h l y
expressed in virtually all poorly differentiated or refrac-
tory cancers studied to date, although its role in this set-
ting is poorly understood [1-23]. HMGA1 (formerly
HMG-I/Y)e n c o d e st h eH M G A 1 aa n dH M G A 1 b( f o r -
merly HMG-I and HMG-Y) chromatin remodeling pro-
teins, which function in modulating gene expression
[16-19]. These protein isoforms result from alternatively
spliced mRNA and differ by 11 internal amino acids
present in the HMGA1a isoform [23-25]. HMGA1 pro-
teins are members of the superfamily of HMG proteins
named for their rapid electrophoretic mobility in polya-
crylamide gels (thus high mobility group). The HMGA
family is distinguished by AT-hook DNA binding
domains that mediate binding to AT-rich regions in the
minor groove of chromatin and includes HMGA1 and
HMGA2 proteins [16,26-33]. After binding to DNA,
HMGA1 proteins recruit additional transcription factors
and histone modifying proteins to alter chromatin struc-
ture and form a higher order transcriptional complex or
enhanceosome [16]. In concert with these factors,
HMGA1 proteins modulate gene expression. Although
its role in transcription is well-established, the down-
stream transcriptional targets regulated by HMGA1 pro-
teins are only beginning to emerge.
HMGA1 proteins were first linked to cancer over 25
years ago when they were discovered as abundant, non-
histone chromatin binding proteins in human HeLa cer-
vical cancer cells [27]. Subsequent studies showed highly
expression levels in poorly differentiated cancers, refrac-
tory hematologic malignancies, and the developing
embryo, with low or undetectable levels in most adult,
differentiated tissues [1-3,5-7,9-27,32-39]. HMGA1 pro-
teins induce oncogenic phenotypes in cultured cells,
including enhanced proliferation, anchorage-indepen-
dent cell growth, migration and invasive properties, and
xenograft tumorigenesis when implanted into immuno-
suppressed mice [2-19]. HMGA1 also promotes meta-
static progression and an epithelial-to-mesenchymal
transition in a breast cancer model [18]. Transgenic
mice misexpressing HMGA1 develop aggressive tumors
involving all three germ layers [6,11,34]. Conversely,
inhibiting HMGA1 expression or function in experimen-
tal models blocks transformation phenotypes such as
proliferation, anchorage-independent cell growth,
tumorigenesis, and metastatic progression
[2,5,10-13,15,18,35,36]. Further, HMGA1 gene expres-
sion and protein levels correlate with adverse clinical
outcomes [11,14-16,37-39]. For example, HMGA1 gene
expression was identified as a marker of poor outcome
in pediatric brain tumors [37]. High HMGA1 protein
levels correlate with poor differentiation in pancreatic
and breast cancers [14,38] and decreased survival in
pancreatic and lung cancers [14,39] by immunohisto-
chemical analysis in primary tumors. More recently,
HMGA1 was identified as a key transcription factor
enriched in embryonic stem cells and poorly differen-
tiated cancers of the breast, bladder, and brain [1].
Expression of HMGA1 and 8 other transcriptional regu-
lators predicted poor survival in these cancers. HMGA1
is also enriched in hematopoietic stem cells [20,21,40].
Together, these studies implicate HMGA1 as a key reg-
ulator in tumor progression, poor differentiation, and
refractory disease.
To better elucidate the role of HMGA1 in tumor pro-
gression, we used genome-wide expression profile analy-
sis in our HMGA1a (herein referred to as HMGA1)
transgenic mouse model for lymphoid malignancy.
These mice succumb to acute lymphoid leukemia by 8-
13 months of age with complete penetrance. Here, we
identified genes dysregulated by HMGA1 early in
tumorigenesis and in well-established tumors. Our stu-
dies reveal distinct pathways activated by HMGA1 at
different stages in tumor development. Although further
studies are needed, our results uncover cellular pathways
that could serve as potential therapeutic targets in lym-
phoid and other tumors with aberrant expression of
HMGA1.
Methods
HMGA1 transgenic mice lymphoid samples
The HMGA1 mice have been previously reported [6,11].
Briefly, the murine Hmga1a cDNA is driven by the H-
2K promoter and immunoglobulin μ enhancer, which is
expressed in B and T cells. All mice develop lymphoid
malignancy by 5-10 months and die from their disease
by 8-13 months [6]. The female mice also develop uter-
ine sarcomas [11]. RNA was isolated from the spleno-
cytes at different stages of developing tumorigenesis,
including 2 months (before the onset of tumors), and at
12 months (when tumors are well established). Splenic
RNA was chosen because these organs are abundant
sources of lymphoid cells and they become uniformly
infiltrated with leukemic cells in all transgenics by 9-12
months. Splenocytes from nontransgenic littermates
were harvested at the same time points as controls.
Isolation of total RNA
Total RNA was isolated from control and transgenic
mouse spleens that were harvested at necropsy and
immediately suspended in RNAlater (Qiagen) to prevent
RNA degradation. From each spleen sample, approxi-
mately 15-30 mg of spleen tissue was homogenized in
RLT buffer (Qiagen) with the Power Gen 700 homoge-
nizer (Fisher Scientific). Total RNA was purified using
the RNeasy Mini kit with DNase treatment (Qiagen) to
eliminate genomic DNA according to the manufacturer’s
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1000 (Thermo Scientific) and purity was assessed with a
2100 Bioanalyzer (Agilent technologies). Total RNA was
isolated from 2 spleens from each age group and pooled
as a single sample to a final concentration of 600 ng/μl
for microarray analysis. Two independent, pooled sam-
ples were prepared at each time point from transgenic
and control mice.
Microarray analysis
The microarray analysis was performed at the Johns
Hopkins University School of Medicine Microarray Core
facility as previously describ e d[ 4 1 - 4 4 ] .B r i e f l y ,m R N A
was converted into double stranded cDNA using a T7-
oligo (dT) promoter primer sequence and purified for
use as a template for in vitro transcription. Transcrip-
tion reactions were performed with T7 polymerase and
biotinylated nucleotide analog/ribonucleotide mix for
cRNA amplification. The biotinylated cRNA was pre-
pared in the hybridization mix with oligonucleotide B2
and four control bacterial and phage cDNA. Labeled
cRNA was hybridized to the Mouse 430 2.0 GeneChip
array (Affymetrix) containing 45,000 probesets corre-
sponding to 21,814 unique genes according to the man-
ufacturer’s instructions. Experiments were performed
with two independent samples at each time point from
the transgenic and control mice. All reported microarray
data are MIAME compliant and stored in the Gene
Expression Ominbus (GEO). The data can be accessed
at GEO under accession number GSE22922.
Data analysis
We used both a parametric statistical approach (Partek
Genomics Suite) and a nonparametric approach [41] to
generate a list of differentially expressed genes. The
overlapping, differentially expressed genes from both
approaches were then analyzed for specific cellular path-
ways and gene set enrichment patterns.
All data were analyzed using the Partek Genomics Suite
v 6 . 4( P a r t e kI n c . ,S t .L o u i s ,M O ,U S A ) .T h ed a t aw a s
adjusted for GC content, normalized with quantile nor-
malization and mean probe summarization by Robust
Multichip Average (RMA) [43,44], and expression fold
change values were determined. Significantly dysregulated
probesets were identified using Spotfire DecisionSite 9
(TIBCO, Palo Alto, CA). Probes were selected if they ful-
filled two criteria: 1) change in expression of ≥ 1.3, and, 2)
a paired p-value indicating significance. Paired p-values
were obtained through Partek’s paired sample t-test to
reduce batch effects by comparing samples prepared at the
same time. We generated lists of probesets with a p ≤ 0.05
in addition to a more selective list with a p ≤ 0.01. Further
pathway and gene set enrichment analysis were conducted
on the dataset with p ≤ 0.05.
As an alternative method to the parametric approach,
a nonparametric approach (Correlative Analysis of
Microarray or CAM) was implemented as previously
described [41] and the results from the two statistical
approaches were compared for concordance. Briefly, the
CAM approach was developed for high-dimensional
data analyses from microarray gene expression studies
with limited sample numbers per comparison group.
Because we noted a batch effect with different scale and
expression distributions in the replicate experiments, we
separately analyzed the data generated from the compar-
ison of the transgenic and control samples from each
experiment and compared the differentially regulated
gene sets between replicates for concordance to identify
a common gene set from each time point.
The list of probesets was filtered for duplicates. All
probesets that were not annotated or ambiguously anno-
tated were checked by BLAST comparison of their
sequences against the online NCBI37/mm9 mouse gen-
ome sequence in the UCSC Genome Browser (Genome
Bioinformatics Group of UC Santa Cruz, CA, USA) to
ensure accuracy.
Pathway analysis
To elucidate cellular pathways regulated by HMGA1
early in tumorigenesis, Ingenuity Pathway Analysis (IPA,
Ingenuity
® Systems, http://www.ingenuity.com) of
selected genes from our microarray data was used. The
IPA score was generated for each comparison and indi-
cates the likelihood that thef o c u sg e n e sp r e s e n ti nt h e
network could have been obtained solely by chance. A
score ≥ 3 was considered significant because it repre-
sents a 1/1,000 chance that the network contains the
specific focus genes by random chance alone [45]. For
each network, pathways or functions from the following
categories were generated: 1.) disease or disorder-related
functions, 2.) molecular and cellular functions, and, 3.)
physiological system development and function. The
pathway with the most significant p value was deter-
mined from each analysis and the top biologic function
was defined as the pathway or function from all cate-
gories with the most significant p value.
Gene set enrichment analysis
Gene set enrichment analysis was performed as pre-
viously described using GSEAv 2 . 0s o f t w a r et oi d e n t i f y
published gene expression profiles that share genes with
the profiles identified in this study (http://www.broad.
mit.edu/gsea) [46,47]. The p value indicates the signifi-
cance of the overlap.
Quantitative real-time PCR validation (qRT-PCR)
The change in expression of candidate genes that were
differentially regulated by HMGA1 by microarray
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performed as we described [6,11], except for the follow-
ing modifications. Total RNA was isolated from mouse
spleens using the RNeasy kit (Qiagen) as recommended
by the manufacturer. cDNA was generated by reverse
transcription of total RNA (500 ng; ABI High Capacity
cDNA Reverse Transcription kit) and subsequently ana-
lyzed by qRT-PCR using the ABI SYBR Green assay kit.
Reaction conditions were 2 min at 50°C, 10 min at 95°
C, followed by 40 cycles of 15 s at 95°C and 60 s at 60°
C. qRT-PCR results were analyzed by normalizing
expression to the internal control glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Primers for all
genes excluding HMGA1 and GAPDH were designed
using the IDT Primer Quest software and the primer
sequences are listed (Table 1). The HMGA1 and
GAPDH primers have been previously reported [11].
Knock-down of HMGA1 in human leukemia cells
HMGA1 expression was knocked-down using siRNA to
HMGA1 (Dharmacon) as we previously described [11],
but with the following modifications. Jurkat cells (5 ×
10
6), a human T-cell acute lymphoblastic cell line,
were transfected with the HMGA1 siRNA (6 ug) by
nucleofection with the Amaxa nucleofector kit V
(Lonza, Inc.) according to the manufacturer’si n s t r u c -
tions. Control Jurkat cells (5 × 10
6) were treated with
the siGenome control non-targeting control siRNA (6
ug; Dharmacon). Cells were subsequently seeded onto
six well plates and collected at 24, 48, and 72 hours
for protein and mRNA. To document HMGA1 knock-
down, both qRT-PCR for mRNA and Western analysis
for protein were performed as previously described
[11].
Results
The genes differentially regulated by HMGA1 early and
late in tumorigenesis
Nonparametric CAM approach
Early in tumorigenesis (at 2 months of age), 46 probes
representing 40 unique genes were significantly up-regu-
lated and 86 probes or 73 unique genes were signifi-
cantly down-regulated in the HMGA1 transgenics
compared to controls in replicate samples by the non-
parametric correlative analysis of microarrays (CAM)
approach [41]. In established tumors at 12 months, 289
probes or 260 unique genes were significantly up-regu-
lated and 246 probes or 165 unique genes were signifi-
cantly down-regulated in the transgenics compared to
controls in replicate samples (Table 2).
Parametric Partek analysis
By the parametric approach [42], 36 genes were differ-
entially regulated by ≥ 1.3-fold with 18 genes up-regu-
lated and 18 down-regulated (p ≤ 0.05) early in
tumorigenesis. With a more stringent p value of ≤ 0.01,
14 genes were differentially regulated by ≥ 1.3-fold with
7 genes up-regulated and 7 down-regulated. In the
established tumors at 12 months, 715 genes were differ-
entially regulated (≥ 1.3 fold) with 283 genes up-regu-
lated and 432 down-regulated (p ≤ 0.05). With the p
value of ≤ 0.01, 152 genes were differentially regulated
by (≥ 1.3-fold) with 63 genes up-regulated and 89 genes
down-regulated (Table 2). There was a very high corre-
lation between the differentially regulated genes
Table 1 Primers for validation of differentially expressed murine and human genes
Gene Forward Primer Reverser Primer RefSeq ID
Mouse Primers
Bub1b TAGTGGCTTTCGGACTGCACAGAT AGACATGGAGGTGCTCCTTGAACA [NCBI:NM_009773.3]
Cd8b1 CTGCTTTGAACTGCTGCAAGCTCT TGGGAGTTCTTGGTTCTTCAGCCA [NCBI:NM_009858.2]
Cxcr3 AACTCAGCCATCCCTGTGTGAGAA ATGGGCACATTCAGTGCTGACAAC [NCBI:NM_009910.2]
Eomes AGGTCGTTCAAGGTGCTGGATTGA TAATAGCACCGGGCACTCGTTCTT [NCBI:NM001 164789.1]
Foxp1 ACTCTGTGCATTGGATGGACCTGT AAGCTGCAGTTCAAAGTCTGCTGC [NCBI:NM001197321.1]
Gzmm ACCTTCTACATCCGGGAAGCCATT GTGGTTTGACATTCTTGCTGGGCT [NCBI:NM_008504.2]
Il18r1 ATCCTGAAGGATGCCGAGTTTGGA TGGTGATGTTGTACCGTGTCCCAT [NCBI:NM001161842.1]
Il2rb TTTCTGGCTTCTTCTCCTGCGTCT AAGGATCTGGGATGTGGCACTTGA [NCBI:NM008368.4]
Human Primers
BUB1B TGGGATGGGTCCTTCTGGAAACTT CACTGTGGCCTCATCATTGGCATT [NCBI:NM001211.5]
CD8B1 ACCTCACAGAAGCTGCTTAACCCA TGAGCGAGGGAGGAATCTGGTAAA [NCBI:NM001178100.1]
CXCR3 ACATAGTTCATGCCACCCAGCTCT TGGGAAGTTGTATTGGCAGTGGGT [NCBI:NM001142797.1]
EOMES CAAATTCCACCGCCACCAAACTGA TTGTAGTGGGCAGTGGGATTGAGT [NCBI:NM_005442.2]
FOXP1 AAACATTTCGGCAATGGTGAGGGC TGCATAATGCCACAGGACTGCAAC [NCBI:NM_001012505.1]
GZMM GTCTGCACTGACATCTTCAAGCCT ATTTATTGGTCCCTCCCTGTCCCT [NCBI:NM005317.2]
IL18R1 CTCCAGAAGGCAAATGGCATGCTT ATTCCTCTTAAGACGTGGCCT [NCBI:NM003855.2]
IL2RB TCCCAAGCCTCCCACTACTTTGAA TGACCCGCACCTGAAACTCATACT [NCBI:NM_000878.2]
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with an R > 0.99 at both the early and late time points.
The cellular pathways dysregulated by HMGA1 early in
tumorigenesis
Nonparametric analysis
To identify pathways regulated by HMGA1 early in
tumorigenesis, we first analyzed the differentially
expressed genes at 2 months identified by CAM using
IPA (Table 3). From the list of differentially regulated
genes, 5 pathways had a significant network score (≥
3.0) and the pathways involved in cell-to-cell signaling
and interaction, hematologic system development and
function, and inflammatory response had the most sig-
nificant network score (score = 50; Figure 1). In this
network, interferon beta (IFNb)i sa ni m p o r t a n tn o d e ,
which functions as a cytokine in antiviral defense and
was previously identified as a transcriptional target of
HMGA1 [16,48-53]. IFNb is involved in cell surface sig-
naling, B cell proliferation, induction of apoptosis, and
the positive regulation of innate immunity. Interferon
alpha (IFNa) is another major node in this network,
which also functions as a cytokine involved in antiviral
defense. In addition, the Nuclear Factor-B( N F B)
transcription factor complex was identified as a major
node and members of this family are known to interact
Table 2 List of probe hits and corresponding genes at each time point
Up-regulated
Age/Tumor status Method Probe Hits Unique Genes Overlap
2 months/Early in tumorigenesis CAM 46 40
Partek (p ≤ 0.05) 19 18 11
Partek (p ≤ 0.01) 7 7 4
12 months/Established tumors CAM 296 260
Partek (p ≤ 0.05) 303 283 71
Partek (p ≤ 0.01) 64 63 16
Down-regulated
Age/Tumor status Method Probe Hits Unique Genes Overlap
2 months/Early in tumorigenesis CAM 86 73
Partek (p ≤ 0.05) 18 18 10
Partek (p ≤ 0.01) 7 7 5
12 months/Established tumors CAM 246 165
Partek (p ≤ 0.05) 470 432 46
Partek (p ≤ 0.01) 92 89 13
The number of differentially expressed probes hits and corresponding unique genes identified by a parametric (Partek) approach or nonparametric (CAM)
approach are shown The overlap of genes identified by both approaches is also shown for p ≤ 0.05 or ≤ 0.01.
Table 3 Top functions by pathway analysis (IPA)
CAM Partek Overlaps CAM Partek Overlaps
2months 2months 2months 12months 12months 12months
Disease & Disorder-
related Function
Inflammatory
response
Inflammatory
response
*Inflammatory
response
Cancer Cancer Cancer
3.57 × 10
-5 - 0.0320 1.61 × 10
-5 - 0.0474 1.93 × 10
-4 - 0.0474 2.71 × 10
-7 -6.96 ×
10
-3
2.84 × 10
-6
-3.44 × 10
-3
1.77 × 10
-5 -.0133
Molecular & Cellular
Functions
*Cellular
development
*Cellular function &
maintenance
Cell-to-cell signaling
& interaction
*Cellular
development
*Cell cycle *Cell cycle
3.58 × 10
-7 -0.0326 1.87 × 10
-6 - 0.0444 1.93 × 10
-4 - 0.0488 7.10 × 10
-13 -7.58 ×
10
-3
1.23 × 10
-11 -
3.09 × 10
-3
2.32 × 10
-8 -.0133
Physiological
System
Development &
Function
Hematological
system
development &
function
Hematological
system
development &
function
Hematological
system
development &
function
Hematological
system
development &
function
Cell-mediated
immune
response
Hematological
system
development &
function
3.06 × 10
-5 -0.0326 2.62 × 10
-6 -0.0474 1.93 × 10
-4 -0.0485 1.89 × 10
-12 -7.26 ×
10
-3
1.27 × 10
-7
-3.09 × 10
-3
3.02 × 10
-6 -.0133
The top functions identified by Ingenuity Pathway Analysis from each category are shown and include: 1.) Diseases and Disorder-related Function, 2.) Molecular
and Cellular Functions, and, 3.) Physiological System Development and Function. * denotes the top biologic function, defined as the function from all3
categories with the most significant IPA score.
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complex or enhanceosome that functions to regulate
gene expression of specific transcriptional targets, such
as IFNb [16,48-53]. NFB plays an important role in
immune function and mediating inflammatory signals.
NFB also appears to have a central role in tumorigen-
esis, particularly in cancers linked to inflammation [54].
JNK, or the family of c-Jun N-terminal kinases, was also
identified as a central node. JNKs were originally defined
as kinases that phosphorylate c-Jun within its transcrip-
tional activation domain and include the mitogen-acti-
vated protein kinases (MAPKs) [55]. These proteins
belong to a family of serine/threonine kinases that mod-
ify the activities of nuclear and mitochondrial proteins
through phosphorylation. MAPKs respond to stress sti-
muli and are involved in inflammation and cytokine
production as well as regulating proliferation, survival,
migration, metabolism, apoptosis, transcription and
translation. The p38 MAPK complex was also identified
as a node and includes MAPK11, MAPK12, MAPK13,
and MAPK14. Like the JNK complex, these protein
kinases also respond to extracellular stress stimuli,
including cytokines, ultraviolet irradiation, heat shock,
and osmotic changes [55,56], transducing extracellular
signals into diverse cellular pathways involved in cellular
homeostasis. The top disease-related function identified
in the network was the inflammatory response while cel-
lular development (which refers to cellular development
and differentiation processes, including hematopoiesis,
maturation and senescence) was the most the top biolo-
gic function and the most significant molecular and cel-
lular function (Table 3). The most significant
physiologic system development and function category
from this network was the hematologic system, which
includes normal development of all hematopoietic cells
(Table 3).
Parametric analysis
We also analyzed the differentially expressed genes at 2
months identified by Partek with IPA. From the list of
differentially regulated genes, there were 6 significant
networks, and the most significant network (score = 23;
Figure 2) was involved in immunological disease, cell-
Figure 1 Network of differentially expressed genes in HMGA1 transgenics at 2 months (nonparametric CAM approach).I P Aw a s
performed on microarray data comparing transgenic to control lymphoid cells from mice. Using 113 differentially expressed genes as the focus
gene set identified by nonparametric analysis, the highest-scoring network was Cell-To-Cell Signaling and Interaction, Hematological System
Development and Function, and Inflammatory Response (score = 50). Red nodes indicate up-regulation; green nodes indicate down-regulation.
Arrows and lines denote interactions between specific genes within the network. A, activation; E, expression regulation; I, inhibition; L,
proteolysis; LO, localization; M, biochemical modification; MB, membership of a group or complex; P, phosphorylation; PD, protein-DNA
interaction; PP, protein-protein interaction; PR, protein-RNA interaction; RB, regulation of binding; RE, reaction; T, transcription; TR, translocation.
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In this network, important nodes include 1.) ERK 1/2
complex (including MAPK1a n dM A P K 2 )w h i c hf u n c -
tion in responding to cellular stress or DNA damage
and induce apoptosis, chemotaxis, migration, prolifera-
tion, and inhibit differentiation [56], and, 2.) the inter-
leukin 12 complex (including IL12A and IL12B), which
function as pro-inflammatory cytokines involved in T-
cell mediated cytotoxicity, natural killer cell-mediated
cytotoxicity, the immune response, cell cycle arrest,
migration, and T cell and B lymphocyte proliferation
[57]. Similar to the IPA analysis of the CAM data at 2
m o n t h s ,J N K ,P 3 8M A P K ,I N F b,a n dN F Bw e r ea l s o
identified as important nodes. Cellular function and
maintenance (which describes functions associated with
the maintenance of cellular homeostasis, such as meta-
bolism, respiration, DNA repair, endoplasmic reticulum
stress response, exocytosis, autophagy, and phagocyto-
sis), was the top biologic function and the most signifi-
cant molecular and cellular function. As with the
nonparametric analysis, the inflammatory response was
the most significant disease-related function and the
hematological system was the most significant physiolo-
gic system function (Table 3). Differentially expressed
genes with a p value of ≤ 0.01 were also assessed by IPA
and identified pathways involved in gene expression, cell
death, and hematologic development and function (see
Additional file 1).
Analysis of concordant genes identified by the parametric
and nonparametric approaches
Finally, we analyzed the overlap of the differentially
expressed genes identified using the nonparametric
CAM and the parametric Partek approaches at 2
months with IPA. There were 4 significant networks,
and the most significant network (score = 30; Figure 3)
was involved with immunological disease, cellular devel-
opment, and cellular function and maintenance. In this
network, the NFB and interleukin 12 complexes were
important nodes. The inflammatory response was the
top biologic function and the most significant disease-
related function. Cell-to-cell signaling interaction was
the most significant molecular and cellular function
(Table 3). As before, the hematologic system was the
Figure 2 Network of differentially expressed genes in HMGA1 transgenics at 2 months (parametric approach). Using 36 differentially
expressed genes as the focus gene set identified by a parametric approach and IPA, the highest-scoring network was Immunological Disease,
Cell-Mediated Immune Response, and Cellular Development (score = 23). Colors, arrows, lines and abbreviations are described under Figure 1.
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Of note, the metastasis suppressor protein 1 (MTSS1)
gene was repressed and appears as a node in networks
from all three analyses early in tumorigenesis (Figures 1,
2, 3). In addition, the EOMES (eomesodermin)s t e mc e l l
gene was up-regulated and identified as a node from all
three analyses. The EOMES gene plays a crucial role in
embryogenesis during both trophoblastic development
and gastrulation. It is also involved in brain develop-
ment and the differentiation of CD8+ T cells.
The transcriptional networks dysregulated by HMGA1 late
in tumorigenesis
Nonparametric analysis
From the list of differentially expressed genes identified
by CAM at 12 months, there were 21 significant net-
works, and the pathway with the most significant net-
work (score = 44) was involved in inflammatory
response, immunological disease, and neurological
disease (Figure 4). In this network, important nodes
included: 1.) interleukin 10, an anti-inflammatory cyto-
kine induced by inflammation, cellular stress, and the
immune response which down-regulates Th1 cytokines
and enhances B cell survival, proliferation, and antibody
production [58], 2.) T-cell receptor complex, which is
involved in T-cell activation [58,59], and, 3.) the NFB
complex, which was also a prominent node in the path-
way analyses at 2 months. In contrast to the pathways
identified early in tumorigenesis, the top disease-related
function was cancer. Cellular development was the top
biologic function and the most significant molecular and
cellular function. As with the analysis early in tumori-
genesis, the hematological system was the most signifi-
cant physiologic system function (Table 3).
Parametric analysis
There were 29 significant networks identified from the
list of differentially expressed genes at 12 months identi-
fied by Partek and the most significant network (score =
Figure 3 Network of differentially expressed genes in transgenics at 2 months (parametric and nonparametric approaches). Using 21
differentially expressed genes as the focus gene set from the overlap of genes identified from the parametric and the nonparametric
approaches and IPA, the highest-scoring network was Immunological Disease, Cellular Development, and Cellular Function and Maintenance
(score = 30). Colors, arrows, lines and abbreviations are described under Figure 1.
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Page 8 of 1648) was involved in DNA replication, recombination,
and repair, cancer, and cell cycle (Figure 5). In this net-
work important nodes included: 1.) The TP53 (tumor
protein 53) tumor suppressor, which is mutated in
many cancers and involved in apoptosis, genomic
instability, inhibition of angiogenesis, and cell cycle
arrest [60], 2.) CDK1 (cyclin dependent kinase 1 or cell
division control protein 2 homolog), which is a highly
conserved serine/threonine kinase that is a key regulator
of cell cycle progression [61], and, 3.) the alcohol group
acceptor phosphotransferases, which include multiple
proteins such as MAPKs, protein kinases, and cyclin
dependent kinases [55,56]. As above, cancer was the
most significant disease-related function. Cell cycle was
the top biologic function and the most significant mole-
cular and cellular function. Cell-mediated immune
response was the most significant physiological system
function (Table 3). Differentially expressed genes with a
pv a l u eo f≤ 0.01 were also assessed by IPA and identi-
fied pathways involved in cancer, gene expression, and
reproductive system disease (see Additional file 1).
Analysis of concordant genes identified by parametric
and nonparametric approaches
We identified 6 significant networks from the overlap of
the differentially regulated genes at 12 months with the
most significant network score (score = 58) involved in
cell cycle, cellular development, and cellular growth and
proliferation (Figure 6). In this network, important
nodes included: 1.) cyclin B1, which regulates the G2/M
transition in cell cycle progression, mitosis, apoptosis,
checkpoint controls, growth and maturation, and is up-
regulated in diverse cancers [62], 2.) cyclin A (including
cyclin A1 and A2), which regulates cell cycle progres-
sion, apoptosis, and checkpoint controls and is also ele-
vated in diverse tumors [63], 3.) the E2F complex, which
includes important regulators of proliferation and cell
cycle progression [64], and, 4.) CDKN2A tumor suppres-
sor, which is involved in apoptosis, cell cycle arrest, and
senescence [65]. The CDKN2A locus is deleted or
silenced in many forms of cancer, including T- and
preB cell leukemia [65]. As before, NFB was a central
node. Cell cycle progression was the top biologic
Figure 4 Network of differentially expressed genes in HMGA1 transgenics at 12 months (nonparametric approach).U s i n g4 2 5
differentially expressed genes as the focus gene set identified from a nonparametric approach and IPA, the highest-scoring network was
Inflammatory Response, Immunological Disease, and Neurological Disease (score = 44). Colors, arrows, lines and abbreviations are described
under Figure 1.
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Page 9 of 16function and the most significant molecular and cellular
function. Cancer was the most significant disease-related
function and the hematological system was the most sig-
nificant physiologic system function (Table 3).
Validation of selected genes dysregulated by HMGA1
To validate our microarray gene expression profile ana-
lysis, we performed qRT-PCR for candidate genes iden-
tified as differentially expressed by microarray analysis
(Table 4). At the early time point in tumorigenesis (2
months), we assessed 6 genes and confirmed differential
expression of all 6 (Table 1), with 5 up-regulated
(CXCR3, EOMES, IL18R1, GZMM, IL2rb)a n d1d o w n -
regulated (FOXP1). Moreover, the fold-changes of these
genes by microarray analysis and qRT-PCR were similar
(Table 4). At the 12 month time point, we assessed
expression of 7 candidate genes and confirmed differen-
tial expression in all cases. Six genes were up-regulated
(BUB1, EOMES, IL18R1, GZMM, IL2rb, CD8b1)a n d
one (FOXP1) was down-regulated. Many of these genes
function in inflammation (CXCR3, EOMES, IL18R1,
GZMM, IL2rb) [66], metastases (CXCR3, BUB1) [66-68],
poor outcome cancers (EOMES, BUB1) [67,68], or stem
cells (EOMES, BUB1) [67-71]. In addition, a subset of
these genes have been identified as markers for poor
outcomes in lymphoid and other cancers (CXCR3,
EOMES, BUB1) [66-68]. Thus, our validation studies
confirmed the differential expression of all of the genes
we assessed (Table 4).
HMGA1 transcriptional targets found in cells from human
lymphoid tumors
To determine if any of the genes dysregulated by
HMGA1 in the transgenic model are relevant to human
lymphoid malignancy, we knocked-down HMGA1 in
Jurkat cells (a human T-cell acute lymphoblastic leuke-
mia or T-ALL cell line) and assessed the expression of
the 8 genes validated in the transgenic model by qRT-
PCR (see Additional file 2). We found that 3 of the 8
genes were also significantly down-regulated in the Jur-
kat T-ALL cells, including EOMES, IL2RB, and CD8B1;
see Additional file 2). These data indicate that a subset
of the genes dysregulated by HMGA1 in our transgenic
model are also relevant in human T-ALL cells.
Figure 5 Network of differentially expressed genes in HMGA1 transgenics at 12 months (parametric approach). Using 715 differentially
expressed genes as the focus gene set, identified by a parametric approach and IPA, the highest-scoring network was DNA Replication,
Recombination and Repair, Cancer, and Cell Cycle (score = 48). Colors, arrows, lines and abbreviations are described under Figure 1.
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Page 10 of 16Geneset enrichment analysis
To determine if the gene expression profiles identified
in our study overlap with previously reported gene sets,
the Molecular Signatures Database (http://www.broad.
mit.edu/gsea) was interrogated [46,47]. We found that
the gene set derived from up-regulated genes in the
established tumors by both the parametric and nonpara-
metric approaches had the most significant overlaps (p
≤ 10
-8) with previously published gene sets (Table 5).
The three gene sets with p ≤ 10
-8 included progenitor T
cells [72], embryonic stem cells [73], and neural stem
cells [73]. The gene set with the highest significant over-
lap (LEE T CELLS 3 UP; p < 2.26E-09) was derived
from a gene expression profile study of human intrathy-
mic T cells at different stages in maturation [73]. The
overlapping gene set from this study was from tran-
scripts enriched in intrathymic T progenitors (ITTP)
and double positive (DP or CD3+/CD4+) T cells com-
pared to more mature T cells. These results indicate
that the HMGA1 tumors share gene expression profiles
with the DP, less differentiated, thymic progenitors. The
second gene set with highly significant overlap
(EMBRYONIC STEM CELL UP; p < 5.53E-09) was
derived from a study of gene expression profiles in
mouse embryonic stem cells compared to differentiated
brain and bone marrow cells [73]. Similarly, the third
gene set was derived from the same study (NEURAL
STEM CELL UP; p < 7.22E-09) and included genes
enriched in neural stem cells compared to differentiated
brain and bone marrow cells [73]. Not surprisingly, this
prior study reported overlap between the embryonic and
neural stem cell gene sets. These results suggest that
HMGA1 drives transcriptional networks that promote
the maintenance of a poorly differentiated, stem-like
phenotype in our transgenic model.
Discussion
Here, we report for the first time cellular pathways
induced by HMGA1 at different stages of tumorigenesis.
Despite its widespread overexpression in virtually all
poorly differentiated tumors and aggressive hematologic
malignancies studied to date [1-23], there were no prior
Figure 6 Network of differentially expressed genes in transgenics at 12 months (parametric and nonparametric approaches). Using 117
differentially expressed genes as the focus gene set identified by both a parametric and nonparametric approach and IPA, the highest-scoring
network was Cell Cycle, Cellular Development, and Cellular Growth and Proliferation (score = 58). Colors, arrows, lines and abbreviations are
described under Figure 1.
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Page 11 of 16studies to identify transcriptional targets dysregulated by
HMGA1 during tumor progression. Moreover, fewer
than 50 bona fide HMGA1 transcriptional targets have
been reported to date [16-18]. The IFNb gene is the
most extensively studied downstream gene target of
HMGA1. HMGA1 binds to the 5’ UTR of this gene and
promotes cooperative binding of NFB (p50/p65) and
additional transcription factors [48-53]. Together with
these factors, HMGA1 bends DNA and forms a tran-
scriptional enhancer complex or “enhanceosome” that is
essential for the expression of this gene. Emerging evi-
dence indicates that HMGA1 is a key transcription fac-
tor in embryonic stem cells and diverse tumors with
poor outcomes [1]. These findings suggest that HMGA1
drives a refractory, stem-like state in cancer by inducing
specific genes and their cellular pathways. Hence, stu-
dies to identify the HMGA1 transcriptome during
tumorigenesis should have important implications, not
only for cancer, but also for development and the stem
cell phenotype.
Early in tumor development, we found that genes
involved in the inflammatory response are dysregulated
by HMGA1. NFB was identified as a key node involved
in HMGA1 signaling, consistent with prior studies
demonstrating that HMGA1 forms an enhanceosome
with NFB [48-53]. Our results also indicate that NFB
is intimately involved with malignant transformation in
this model, both early in tumor initiation, and later, in
established tumors. Notably, most of the previously
reported HMGA1 transcriptional targets include NFB
regulatory elements in their promoter regions and many
participate in mediating inflammatory pathways [[16],
Resar and Sumter unpublished data]. Given the recent
evidence that inflammation is a precursor lesion in
some cancers, this link between HMGA1, NFB, and
inflammation are consistent with a model whereby these
proteins cooperate to induce inflammatory signals and
drive transformation. This result also opens up potential
avenues for therapeutic and even preventive interven-
tions to block tumor initiation and/or progression. In
preliminary studies, we found that crossing the HMGA1
transgenics with mice null for the p50 subunit of NFB
results in an increase in lymphoid tumor burdens (Bel-
ton & Resar, unpublished data). The NFBt r a n s c r i p -
tional complex is comprised primarily of p65:p50
heterodimers in which p65 functions as an activator,
and p50, which lacks a transcriptional activation
domain, is thought to function as an inhibitor. The p50/
p65 heterodimers are thought to activate transcription
of canonical NFB genes, whereas p50 homodimers
repress transcription. Indeed, mice deficient in p50 have
been shown to have enhanced NFB activity and inflam-
matory responses [74]. Although further confirmatory
studies are needed, our preliminary results suggest that
excess NFB activation (with loss of inhibition by p50)
could lead to enhanced tumorigenesis induced by
HMGA1.
The up-regulation of inflammatory pathways during
HMGA1-induced tumorigenesis is also consistent with
our previous studies demonstrating that anti-inflamma-
tory agents (sulindac and celecoxib) interfere with sarco-
mas in our HMGA1 transgenics [12]. The anti-
inflammatory drugs did not significantly affect the lym-
phoid tumors, however, suggesting that COX-2 may not
be consistently up-regulated in these tumors. Indeed, we
assessed COX-2 expression in the lymphoid tumors and
found up-regulation in only 50% of lymphoid cells early
in tumorigenesis; it was not up-regulated in the estab-
lished tumors (see Additional file 3). Moreover, the
tumor size was decreased in ~50% of the treated
tumors, suggesting that the inhibitors function only in
Table 4 Comparison of microarray and qRT-PCR results
for selected genes
Early/2 months Microarray qRT-PCR
Gene Symbol Fold-change Fold-change p-value
Cxcr3 1.534 1.604 7.13E-05
Eomes 1.460 1.610 1.29E-02
FoxP1 -1.326 -1.512 3.30E-04
Gzmm 4.297 11.452 5.41E-06
IL18r1 1.399 2.096 2.15E-03
IL2rb 1.566 1.415 6.03E-03
Late/12 months Microarray qRT-PCR
Gene Symbol Fold-change Fold-change p-value
Bub1b 1.618 1.423 3.82E-07
CD8b1 2.541 1.889 2.76E-02
Eomes 2.327 2.073 1.28E-02
FoxP1 -2.593 -2.045 9.80E-05
Gzmm 10.424 24.514 8.60E-03
IL18r1 2.085 2.042 2.88E-02
IL2rb 1.821 1.516 3.61E-02
A subset of genes identified as differentially expressed by microarray analysis
were validated by qRT-PCR at both the early and late time points. The fold-
change found by microarray and qRT-PCR were similar for all genes assessed
by qRT-PCR.
Table 5 Gene sets that overlap with the HMGA1 gene
sets
Up-regulated Genes in Established Tumors
Gene set name p value
LEE TCELLS3 UP 2.26E-09
STEMCELL EMBRYONIC UP 5.53E-09
STEMCELL NEURAL UP 7.22E-09
The Molecular Signature Database was interrogated for overlaps with the
gene sets identified in our analyses. The most significant overlaps (p ≤ 10
-8)
are shown above with the relevant p value. (See Additional file 4 for all
overlaps identified.)
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Page 12 of 16tumors up-regulating COX-2. We also identified the
IFNb gene as a node involved in HMGA1 function early
in tumorigenesis, which further validates both our
model system and experimental approach because this is
an established HMGA1 target gene. Moreover, we
uncovered additional cytokine nodes that further sup-
port the role of HMGA1 in driving inflammatory path-
ways during lymphoid tumorigenesis, including IFNa
and IL-12. In addition, JNK, ERK1/2 and MAP kinases
were key nodes early in tumorigenesis, additional path-
ways that could be pharmacologically manipulated in
therapy. Interestingly, all networks from this early time
point show down-regulation of the MTSSI gene, which
encodes the metastasis suppressor protein 1. Repressing
a suppressor of metastases represents a previously unde-
scribed pathway through which HMGA1 promotes
tumor progression. The EOMES gene was also up-regu-
lated in all networks and this gene is crucial in embryo-
nic development. Previous studies also show that
EOMES are overexpressed in colorectal cancer [75].
Later in tumorigenesis, we identified genes involved
in cell cycle progression as a central pathway.
Although HMGA is thought to induce cellular prolif-
eration in some settings [16], its role in cell cycle pro-
gression has not been extensively studied and warrants
further investigation, particularly because cell cycle
inhibitors are available and newer agents are under
development. Our results suggest that HMGA1 up-reg-
ulates expression of the E2F proliferation genes, and at
least three key cyclins or cyclin complexes, including
the cyclin A complex, cyclin B1, and cyclin E, the lat-
ter of which is a downstream transcriptional target of
E2F1. These findings are consistent with previous stu-
dies in adipocytes expressing a carboxyl-terminal, trun-
cated HMGA1 that showed increased E2F1 protein
levels and E2F1 DNA binding activity [76]. Subsequent
studies demonstrated that HMGA1 interacts with the
RB protein and interferes with RB-mediated repression
of E2F1 transcription and cell cycle progression in
neuroblastoma cells [77].T h u s ,H M G A 1c o u l dp r o -
mote tumor progression by inducing a molecular pro-
gram for cell cycle progression and proliferation with
up-regulation of E2F1 and cyclins. CDK1 was also
identified as a node in the parametric analysis of dif-
ferentially expressed genes in the established tumors,
which could further augment cyclin function through
activation by phosphorylation. The TCR complex was
identified as a node in the nonparametric analysis and
functions in T cell activation and function. Interest-
ingly, HMGA1 null mice have a paucity of T cells,
further substantiating an important role for HMGA1
in T cell development and function [78]. In addition,
two prominent tumor suppressor loci were identified
as major nodes in the established tumors, namely
CDKN2A and TP53.N o t a b l y ,t h eCDKN2A locus is
deleted in up to 90% of cases of T-cell leukemia [65],
while this locus is silenced through methylation in
other forms of leukemia. The CDKN2A locus encodes
the Ink4a and Arf tumor suppressor proteins which
function upstream of Rb and p53, respectively, and
serve to maintain the tumor suppressor function of Rb
and p53. It is not clear if CDKN2A is mutated in our
mouse tumors, although we have preliminary evidence
that expression of at least the INK4A is decreased in a
subset of the lymphoid tumors (Resar, unpublished
data). TP53, the other tumor suppressor node identi-
fied in our analysis, is among the most frequently
mutated tumor suppressors in cancer with mutations
occurring in most human tumors. TP53 functions by
helping cells respond to DNA damage and other cellu-
lar stresses, acting as a “gate keeper” of the integrity of
the genome [60]. It is possible that TP53 is inactivated
through INK4A/ARF mutation or inactivation in our
tumor model, similar to Myc-induced lymphoid
tumors in mice [79,80]. Future studies are needed to
assess the functional status of these tumor suppressors
in the HMGA1 transcriptional networks and are likely
to uncover additional pathways that could be targeted
in hematologic and other malignancies driven by
HMGA1.
We also found that gene sets regulated by HMGA1
overlap with stem cell gene sets, including embryonic
and neural stem cells compared to differentiated cells.
The gene set enrichment analysis also showed overlap
with immature T cells. These results indicate that
HMGA1 drives transcriptional pathways shared by
poorly-differentiated, stem-like cells. Because prior stu-
dies demonstrate that cancers with stem-like molecular
signatures have poor outcomes [1], it is likely that
HMGA1 drives a refractory, advanced tumor by indu-
cing these pathways in tumor cells. HMGA1 is also
highly expressed during embryogenesis and it may regu-
late similar cellular pathways during development and
promote tumorigenesis when these pathways are re-acti-
vated in the postnatal period.
Conclusions
Here, we found that HMGA1 induces genes involved in
inflammatory pathways early in lymphoid tumorigenesis
and genes involved in embryonic stem cells, cell cycle pro-
gression, and proliferation in established tumors. HMGA1
also dyregulates genes and pathways that function in stem
cells, cellular development and hematopoiesis at both
early and late stages of tumorigenesis. These results pro-
vide insight into HMGA1 function at different stages in
tumor development and point to cellular pathways that
could serve as therapeutic targets in lymphoid and other
human cancers with aberrant HMGA1 expression.
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Additional file 1: Table and networks of differentially expressed
genes with p ≤ 0.01. A.) Table of all differentially expressed genes in
the HMGA1 mice compared to controls at 2 months and 12 months
with a p ≤ 0.01. B.) Network of differentially expressed genes identified
by a parametric approach in the HMGA1 transgenic mice at 2 months
with a p ≤ 0.01. C.) Network of differentially expressed genes identified
by a parametric approach in the HMGA1 transgenic mice at 12 months
with a p ≤ 0.01.
Additional file 2: Data from HMGA1 knock-down in human
leukemia cells (Jurkat T-cell ALL cells). Data from knock-down of
HMGA1 in Jurkat cells are shown, including mRNA and protein
expression for HMGA1 and mRNA expression for CD8B1, EOMES, and
IL2RB.
Additional file 3: COX-2 data from HMGA1 and control mice. COX-2
mRNA expression in the spleens from HMGA1 or control mice at 2
months is shown.
Additional file 4: Gene set enrichment analysis. This file includes all
overlaps with our gene sets identified by gene set enrichment analysis.
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